Type C Meeting Requested to Accelerate XRx-026 for Gout to NDA ● CALGARY, Alberta, Feb. 24, 2025 (GLOBE NEWSWIRE) -- XORTX ...
GlobalData on MSN3d
Phoenix Molecular kicks off Phase II part of breast cancer combo trialThe Phase II portion is seeking to establish safety and efficacy of the company’s HER2 breast cancer therapy in combination ...
XORTX Therapeutics (XRTX) has submitted a Type C meeting request with the US Food and Drug Administration regarding the Company’s XRx-026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback